WALTHAM, Mass., Oct. 24, 2023 /PRNewswire/ -- Affinia Therapeutics ('Affinia'), an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies for rare and prevalent devastating diseases, today announced that the company will present preclinical data on its novel AAV capsids for skeletal muscle, cardiac muscle, and central nervous system (CNS) in a poster session at the 30th European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress, being held October 24-27, 2023, in Brussels, Belgium..

沃尔瑟姆，马萨诸塞州。，2023年10月24日/PRNewswire/-Affinia Therapeutics（'Affinia'），一家创新的基因治疗公司，为合理设计的腺相关病毒（AAV）载体和罕见和流行的破坏性疾病的基因治疗提供专有平台，今天宣布该公司将为骨骼肌，心肌，和中枢神经系统（CNS）在2023年10月24日至27日在比利时布鲁塞尔举行的第30届欧洲基因和细胞治疗学会（ESGCT）2023年会上的海报会议上。。

The poster presentation details are listed below and the full program can be found on the ESGCT website at www.esgctcongress.com.

海报展示详情如下所示，完整程序可在ESGCT网站www.esgctcongress.com上找到。

Title: Engineered AAV capsids with significantly improved muscle and CNS tropism plus reduced liver and DRG expression compared to AAV9Abstract Number: P084Date: October 25, 2023, 6:15-7:30 PM CEST and October 26, 2023, 7:30-8:30 PM CESTPresenter: John Reece-Hoyes, Ph.D., Senior Director, Head of Vector Biology, Affinia.

题目：与AAV9相比，工程化AAV衣壳具有显着改善的肌肉和CNS向性以及降低的肝脏和DRG表达摘要编号：P084Date:2023年10月25日，下午6:15-7:30 CEST和2023年10月26日，7:30-8:30 PM CEST主持人：John Reece Hoyes博士，Affinia病媒生物学高级主任。

About Affinia TherapeuticsAffinia Therapeutics is pioneering a shift to a new class of rationally designed gene therapies that treat rare and prevalent diseases. Affinia Therapeutics' proprietary Affinia Rationally designed Therapeutics (ART) platform consists of three pillars intended to synergistically improve the efficacy, safety, and manufacturability of adeno-associated virus (AAV)-based gene therapies through the development of next-generation capsids, promoters, and manufacturing approaches. For more information, visit https://www.affiniatx.com..

关于Affinia Therapeutics Affinia Therapeutics正在开创转向一类新的合理设计的基因疗法，治疗罕见和流行的疾病。Affinia Therapeutics专有的Affinia合理设计的治疗（ART）平台由三大支柱组成，旨在通过开发下一代衣壳协同提高基于腺相关病毒（AAV）的基因疗法的功效，安全性和可制造性，推动者和制造方法。欲了解更多信息，请访问https://www.affiniatx.com..

SOURCE Affinia Therapeutics

来源Affinia Therapeutics